Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.


a synthetic anticholinergic used as an antispasmodic to help treat peptic ulcer and other gastrointestinal disorders, a preanesthetic antisialagogue to decrease salivation and respiratory secretions associated with anesthesia, and an antiarrhythmic to counteract arrhythmias associated with induction of anesthesia or surgery; administered orally, intramuscularly, or intravenously.

glycopyrrolate (glycopyrronium (UK))

Robinul, Robinul Forte

Pharmacologic class: Anticholinergic

Therapeutic class: Antispasmodic, antimuscarinic, parasympatholytic

Pregnancy risk category B


Inhibits action of acetylcholine on muscarinic receptors that mediate effects of parasympathetic postganglionic impulses. This inhibition relaxes cardiac smooth muscle, inhibits vagal reflexes, and decreases tracheal and bronchial secretions.


Injection: 0.2 mg/ml

Tablets: 1 mg, 2 mg

Indications and dosages

Adjunct in peptic ulcer disorders

Adults: 1 mg P.O. t.i.d. or 2 mg (Forte) two to three times daily, to a maximum of 8 mg/day; or 0.1 to 0.2 mg I.M. or I.V. three or four times daily

To diminish secretions and block cardiac vagal reflexes before surgery

Adults and children ages 2 and older: 0.0044 mg/kg I.M. 30 to 60 minutes before anesthesia

Children ages 1 month to 2 years: 0.0088 mg/kg I.M. 30 to 60 minutes before anesthesia

To diminish secretions and block cardiac vagal reflexes during surgery

Adults: 0.1 mg I.V. May repeat as needed at 2- to 3-minute intervals.

Children: 0.004 mg/kg I.V., not to exceed 0.1 mg as a single dose. May repeat at 2- to 3-minute intervals.

To diminish or block cholinergic effects caused by anticholinesterase

Adults and children: 0.2 mg I.V. for each 1 mg neostigmine or 5 mg pyridostigmine. May give I.V. undiluted or with dextrose injection by infusion.

Off-label uses

• Sweating


• Hypersensitivity to drug
• Arrhythmias
• Chronic obstructive pulmonary disease
• GI disease, infection, atony or ileus
• Myasthenia gravis
• Glaucoma
• Obstructive uropathy
• Severe prostatic hypertrophy


Use cautiously in:
• cardiovascular disease, heart failure, hypertension, renal or hepatic disease, Down syndrome, hyperthyroidism, hiatal hernia, ulcerative colitis, mild to moderate prostatic hypertrophy, autonomic neuropathy, spasticity, suspected brain damage
• pregnant or breastfeeding patients.


• Give oral dose 30 to 60 minutes before meals.
• For I.V. injection, give either undiluted or diluted with dextrose 5% or 10% in water or saline solution. Give each 0.2 mg over 1 to 2 minutes.

Keep resuscitation equipment on hand to treat curare-like effects of overdose.

Adverse reactions

CNS: weakness, nervousness, insomnia, drowsiness, dizziness, headache, confusion, excitement

CV: palpitations, tachycardia

EENT: blurred vision, photophobia, mydriasis, increased intraocular pressure, cycloplegia

GI: nausea, vomiting, constipation, abdominal distention, epigastric distress, heartburn, gastroesophageal reflux, dry mouth, paralytic ileus

GU: urinary hesitancy or retention, lactation suppression, erectile dysfunction

Skin: urticaria, decreased sweating or anhidrosis

Other: loss of taste, fever, allergic reaction, irritation at I.M. injection site, anaphylaxis, malignant hyperthermia


Drug-drug.Amantadine, antihistamines, antiparkinsonian drugs, disopyramide, glutethimide, meperidine, phenothiazines, procainamide, quinidine, tricyclic antidepressants: additive anticholinergic effects

Patient monitoring

Check for signs and symptoms of anaphylaxis and malignant hyperthermia.
• Monitor neurologic and cardiovascular status.

Assess for curare-like effects (neuromuscular blockade leading to muscle weakness and possible paralysis), which indicate overdose.
• Assess fluid intake and output. Have patient void before each dose to avoid urinary retention.

Patient teaching

• Advise patient to take oral dose 30 to 60 minutes before meals.

Tell patient to immediately report signs and symptoms of serious adverse effects, especially anaphylaxis.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration, vision, and alertness.
• Tell patient to minimize GI upset by eating frequent, small servings of food and drinking adequate fluids.
• Advise patient to report urinary hesitancy or retention.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.


/gly·co·pyr·ro·late/ (-pir´o-lāt) a synthetic anticholinergic used as a gastrointestinal antispasmodic, a preanesthetic antisialagogue, and an antiarrhythmic for anesthesia- or surgery-associated arrhythmias.


an anticholinergic.
indications It is prescribed as an adjunct to ulcer therapy and parenterally to reduce secretions before surgery.
contraindications Narrow-angle glaucoma, asthma, obstruction of the genitourinary or GI tract, ulcerative colitis, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are blurred vision, central nervous system effects, tachycardia, dry mouth, decreased sweating, and hypersensitivity reactions.

glycopyrrolate, glycopyrronium

an anticholinergic used to reduce gastric acid secretion and hypermotility.
References in periodicals archive ?
Glycopyrrolate received orphan drug designation from the FDA, which is intended to provide incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the U.
We have delivered another quarter of strong financial results while significantly increasing our R&D investments, which has enabled us to in-license new products and complete the patient enrollments of our Phase III clinical trials for both Glycopyrrolate and the Pravastatin/Fenofibrate combination," said Patrick Fourteau, President and Chief Executive Officer of Sciele Pharma.
Poster Details Date & Time: Sunday, September 25, 2011; 12:50pm - 2:40pm Thematic Poster Session: Bronchodilators in asthma and COPD; Session 96 Title: "Fixed combination of glycopyrrolate and formoterol MDI (GFF MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled Phase 2b study in patients with COPD"
The seven studies on adjunct/alternate therapies in human poisoning included three studies on haemoperfusion (12-14), one systematic review on alkalinisation (15) and one study each on magnesium (16), plasma (9) and glycopyrrolate (17).
The Company's Glycopyrrolate product is currently in Phase III clinical trials to treat chronic moderate-to-severe drooling in pediatric patients.
In the first quarter of 2007, the Company began enrolling patients in its pivotal Phase III safety study using glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients.
Do not use Seebri Neohaler if you are allergic to glycopyrrolate or any of the ingredients in Seebri.
2 mg of glycopyrrolate, and no further interventions were needed.
Also, some of the newer long-acting antimuscarinic agents (LAMAs) include drugs such as aclidinium and glycopyrrolate.
Glycopyrrolate is administered to decrease patient secretions.
Glycopyrrolate is a quaternary ammonium compound used perioperatively to reduce salivary and respiratory secretions.